Interaction of genetic counselors with molecular genetic testing laboratories: Implications for non-geneticist health care providers

American Journal of Medical Genetics

Volumn 119 A, Issue 3, 2003, Pages 297-301

  McGovern, Margaret M ^a,b   Benach, Marta ^a   Zinberg, Randi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Genetic laboratory reports; Molecular genetic testing

Indexed keywords

ARTICLE; CONFIDENTIALITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; GENE IDENTIFICATION; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE; HUMAN; INFECTION RISK; INFORMED CONSENT; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; PATIENT SATISFACTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PRIVACY;

EID: 0041320991     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.20196     Document Type: Article

References (13)

1. American College of Medical Genetics. 2001. http://www.acmg.net.
2. Andrews L, Fullarton JE, Holtzman NA, Motulsky AG, editors. 1994. Assessing genetic risks: Implications for health and social policy. Washington, DC: National Academy Press.
3. Barber Y, Rubio C, Fernandez E, Rubio M, Fibla JJ. 2001. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users. Infect Dis 184:1279-1288.
4. Geller G, Tambor ES, Chase GA, Hofman KJ, Faden RR, Holtzman NA. 1993. Incorporation of genetics in primary care practice, will physicians do the counseling and will they be directive? Arch Fam Med 2:1119-1125.
5. Giardiello FM, Brensinger J, Petersen GM, Luce MC, Hylind LM, Bacon JA, Booker SV, Parker RD, Hamilton SR. 1999. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. N Engl J Med 336:823-827.
6. Hofman K. 1993. Physicians' knowledge of genetics and genetic tests. Acad Med 68:625-632.
7. Holtzman NA, Watson MS, editors. 1997. Promoting safe and effective genetic testing in the United States: Final report of the task force on genetic testing. Washington, DC.
8. Hsieh LL, Liou SH, Chen YH, Tsai LC, Yang T, Wu TN. 2000. Association between aminolevulinate dehydrogenase genotype and blood lead levels in Taiwan. J Occup Environ Med 42:151-155.
9. Krynetski EY, Evans ME. 1998. Pharmacogenetics of cancer therapy: Getting personal. Am J Hum Genet 63:11-16.
10. Preconception and Prenatal Carrier Screening for Cystic Fibrosis. 2001. American College of Obstetrics and Gynecology and the American College of Medical Genetics.
11. Sandhaus LM, Singer ME, Dawson NV, Wiesner GL. 2001. Reporting BRCA test results to primary care physicians. Gen in Med 3:327-334.
12. Secretary's Advisory Committee on Genetic Testing (SACGT). 2000. Enhancing the oversight of genetic testing: Recommendations of the SACGT http://ww4.od.nih.gov/oba/sacgt/reports/oversight_report.pdf.
13. U.S. Congress. 1992. Office of technology assessment, cystic fibrosis, and DNA Tests: Implications for carrier screening, OTA-BA-532 (Washington, DC: U.S. Government Printing Office, August 1992).